This differential regulation of HMMR was validated in LNCaP (Fig. 1b, c), VCaP (Supplementary Figure 1a, b) and V16D (Supplementary Figure 1c, d) PCa cells, where HMMR gene and protein expression were unaffected by enzalutamide compared to vehicle treatment, but significantly downregulated by two independent siRNA targeted to AR (siAR) compared to scrambled control siRNA (siCON). This evidence concerns the gene AR and posterior cortical atrophy.